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Abstract
Background:  The  critically  ill  patient  can  develop  gastric  erosions  and,  on  occasion,  stress  ulcers
with severe  gastrointestinal  bleeding  that  can  be  fatal.
Aims:  The  purpose  of  this  review  was  to  provide  current  information  on  the  pathophysiology,
risk factors,  and  prophylaxis  of  digestive  tract  bleeding  from  stress  ulcers  in  the  intensive  care
unit.
Methods:  We  identiﬁed  articles  through  a  PubMed  search,  covering  the  years  1970  to  2013.  The
most relevant  articles  were  selected  using  the  search  phrases  ‘‘stress  ulcer’’,  ‘‘stress  ulcer
bleeding prophylaxis’’,  and  ‘‘stress-related  mucosal  bleeding’’  in  combination  with  ‘‘intensive
care unit’’.
Results:  The  incidence  of  clinically  signiﬁcant  bleeding  has  decreased  dramatically  since  1980.
The most  important  risk  factors  are  respiratory  failure  and  coagulopathy.  Proton  pump  inhibitors
(PPIs) or  H2  receptor  antagonists  (H2RAs)  are  used  in  stress  ulcer  bleeding  prophylaxis.  Both
drugs have  been  shown  to  be  superior  to  placebo  in  reducing  the  risk  for  gastrointestinal  bleeding
and PPIs  are  at  least  as  effective  as  H2RAs.  Early  enteral  feeding  has  been  shown  to  reduce  the
risk for  stress  ulcer  bleeding,  albeit  in  retrospective  studies.
Conclusions:  Admittance  to  the  intensive  care  unit  in  itself  does  not  justify  prophylaxis.  PPIs
are at  least  as  effective  as  H2RAs.  We  should  individualize  the  treatment  of  each  patient  in  the
intensive  care  unit,  determining  risk  and  evaluating  the  need  to  begin  prophylaxis.
© 2013  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  All
rights reserved.
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PALABRAS  CLAVE
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bomba  de  protones;
Antagonistas  de  los
receptor  H2
Proﬁlaxis  para  sangrado  por  ulceras  de  estrés  en  la  unidad  de  cuidados  intensivos
Resumen
Antecedentes:  El  paciente  críticamente  enfermo  puede  desarrollar  erosiones  gástricas  y,  en
ocasiones, úlceras  por  estrés  con  sangrado  gastrointestinal  grave  que  puede  ser  fatal.
Objetivos:  El  propósito  de  esta  revisión  fue  proporcionar  información  actualizada  acerca  de
la ﬁsiopatología,  factores  de  riesgo  y  proﬁlaxis  por  sangrado  del  tubo  digestivo  causado  por
ulceras de  estrés  en  la  unidad  de  cuidados  intensivos.
Métodos:  Identiﬁcamos  artículos  a  través  de  una  búsqueda  en  PubMed,  que  abarcaba  de  los
an˜os 1970  a  2013.  Los  artículos  más  relevantes  fueron  seleccionados  utilizando  las  frases  de
búsqueda  «úlceras  de  estrés»,  «proﬁlaxis  de  sangrado  por  úlceras  de  estrés» y  «sangrado  de  la
mucosa relacionado  con  el  estrés» en  combinación  con  «unidad  de  cuidados  intensivos».
Resultados:  La  incidencia  de  sangrado  clínicamente  signiﬁcativo  ha  disminuido  drásticamente
desde 1980.  Los  factores  de  riesgo  más  importantes  son  el  fallo  respiratorio  y  las  coagulopatías.
Los inhibidores  de  la  bomba  de  protones  (IBP)  o  los  antagonistas  de  receptores  H2  (H2RA)  se
utilizan en  la  proﬁlaxis  de  sangrado  por  úlceras  de  estrés.  Ambos  medicamentos  han  mostrado
ser superiores  al  placebo  en  la  reducción  del  riesgo  de  sangrado  gastrointestinal,  y  los  IBP  son
por lo  menos  tan  efectivos  como  los  H2RA.  Se  ha  mostrado  que  la  alimentación  enteral  temprana
reduce el  riesgo  de  sangrado  por  úlceras  de  estrés,  aunque  solo  en  estudios  retrospectivos.
Conclusiones:  La  hospitalización  en  la  unidad  de  cuidados  intensivos  por  sí  sola  no  justiﬁca  la
proﬁlaxis. Los  IBP  son  por  lo  menos  tan  efectivos  como  los  H2RA.  Debemos  individualizar  el
tratamiento  de  cada  paciente  en  la  unidad  de  cuidados  intensivos,  determinando  el  riesgo  y
evaluando  la  necesidad  de  comenzar  la  proﬁlaxis.
© 2013  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Todos los  derechos  reservados.
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The  critically  ill  patient  may  develop  gastric  erosions  and,
at  times,  stress  ulcers  with  severe  gastrointestinal  bleeding
that  can  be  fatal.  Stress  ulcers  are  gastric  mucosa  injuries,
associated  with  stressful  events  such  as  extensive  burns,
mechanical  ventilation,  major  surgery,  sepsis,  coagulopa-
thy,  and  severe  trauma.1 The  purpose  of  this  review  is  to
present  an  update  of  the  incidence,  risk  factors,  pathophysi-
ology  and  prevention  of  stress  ulcer  bleeding  in  the  intensive
care  unit.
Methods
Relevant  articles  in  the  English  language  literature  were
identiﬁed  through  a  PubMed  search  (1970-March/2013)  using
the  search  terms  «stress  ulcer», «stress  ulcer  prophylaxis»,
and  «stress  related  mucosal  bleeding» in  combination  with
«intensive  care  unit». We  selected  clinical  reviews,  ran-
domized  clinical  trials,  meta-analyses,  and  therapeutic
guidelines.  We  extracted  data  on  pathophysiology,  epidemi-
ology,  risk  factors,  and  prophylaxis.  It  was  not  our  objective
to  perform  a  systematic  review.
Pathophysiology
The  pathogenesis  of  stress-related  mucosal  disease  and
stress  ulcers  is  multifactorial.2 One  important  factor  is
splanchnic  hypoperfusion  due  to  stress-related  effects
associated  with  critical  illness.  These  effects  include  sympa-
thetic  nervous  system  activation,  increased  catecholamine
t
r
a
celease  and  vasoconstriction,  hypovolemia,  decreased  car-
iac  output,  and  release  of  proinﬂammatory  cytokines.  The
tress-related  responses  damage  the  integrity  of  the  gas-
ric  mucosa  by  reducing  gastrointestinal  blood  ﬂow,  oxygen
elivery,  and  bicarbonate  secretion.  As  the  mucosal  barrier
ermeability  is  compromised,  back-diffusion  of  hydrogen
ons  and  pepsin  further  damages  the  mucosal  epithelial
ayer.  Slowed  mucosal  blood  ﬂow  impairs  mucosal  heal-
ng.  Decreased  gastric  motility  prolongs  acid  contact  time
ith  the  gastric  mucosa,  increasing  the  risk  of  ulceration.
nother  factor  is  reperfusion  injury.  When  blood  ﬂow  is
estored  after  long  periods  of  hypoperfusion,  elevated  nitric
xide  synthase  levels  lead  to  hyperemia,  cell  death,  and
nhanced  inﬂammatory  response.  This  results  in  further  GI
pithelial  damage  and  ulceration.  Stress-related  mucosal
esions  are  typically  located  in  the  acid-producing  areas  of
he  stomach  (i.e.  upper  body  and  fundus).  Common  endo-
copic  ﬁndings  range  from  superﬁcial  erosions  to  deep  focal
lcers  that  penetrate  the  submucosa,  generally  occurring
etween  the  third  and  seventh  day  after  intensive  care  unit
ICU)  admission.3
pidemiology
mportant  bleeding  from  stress  ulcers  is  not  a  frequent
vent.  Endoscopic  evidence  of  mucosal  damage  is  seen  in
ost  patients,  74  to  100%,  within  hours  of  admission  tohe  ICU.4 Occult  bleeding  (guaiac  positive  stools)  prevalence
anges  from  15  to  50%.5 Overt  bleeding  is  seen  between  5
nd  25%  of  critically  ill  patients.5--8 The  incidence  of  clini-
ally  important  bleeding  (i.e.  tachycardia,  hypotension,  and
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eed  for  blood  transfusion)  has  declined  since  1980  to  ranges
etween  3.7%  in  patients  with  risk  factors  to  0.1%  in  patients
ith  no  risk  factors.9--12.
Decreased  incidence  of  major  bleeding  can  be  explained
y  technological  advances  that  have  improved  patient  rean-
mation  in  the  intensive  care  unit  such  as  optimization  of
emodynamic  status,  better  tissue  oxygenation,  successful
reatment  of  sepsis,  and  early  enteral  feeding  instead  of  PPI
nd  H2RA  use.13,14
Nosocomial  gastrointestinal  bleeding  due  to  stress  ulcers
s  associated  with  higher  in-hospital  mortality  rates,  com-
only  in  the  intensive  care  unit.13,15 This  has  encouraged
he  prophylactic  administration  of  several  drugs,  such  as
ntacids,  sucralfate,  H2RAs,  and  PPIs.
Antacids  and  sucralfate  are  no  longer  used  in  most  inten-
ive  care  units.  H2RAs  reduce  gastric  acid  secretion  through
 reversible,  competitive  inhibition  of  histamine-stimulated
cid  secretion  and  is  frequently  associated  with  tachyphy-
axis  (reduced  effect  after  48  h  of  use).  PPIs  irreversibly
uppress  gastric  acid  production  at  the  hydrogen/potassium-
denosine  triphosphate  level,  providing  long-lasting  inhibi-
ion,  and  are  the  most  potent  antisecretory  agents  currently
vailable.  Unlike  H2RAs,  PPIs  inhibit  both  histamine-induced
nd  vagally-mediated  gastric  acid  secretion.
In  recent  years,  PPIs  have  become  the  most  frequently
sed  drugs,  in  relation  to  H2RAs,  for  preventing  stress
lcers  and  gastrointestinal  bleeding.  However,  it  has  been
hown  that  overuse  of  these  drugs  in  patients  with  no  risk
actors  in  the  intensive  care  unit,  as  well  as  in  non-ICU
ospitalized  patients,  is  a  very  frequent  event.  This  inap-
ropriate  prescription  has  increased  both  the  adverse  effect
ate  and  hospitalization  costs.16--19 Likewise,  prescription  of
hese  drugs  is  usually  continued  once  the  patient  is  out
f  the  hospital,  with  the  same  consequences  in  relation
o  adverse  effects  and  costs.20 In  2006,  gastric  secretion
nhibitor  sales  in  England  rose  to  £ 425  m  (D  527  m;
01  m  USD).  Approximately  25  to  70%  of  those  prescriptions
ad  no  clear  indication.19
The  administration  of  these  drugs  over  a  long  period
f  time  is  not  harmless.  The  main  complications,  albeit
ncommon  are:  increased  risk  of  nosocomial  and  community
cquired  pneumonia21,  low  calcium  absorption  with  osteo-
orosis  and  risk  of  hip  fracture22,23,  and  increased  risk  of
lostridium  difﬁcile  infection.24--26
isk factors for stress related mucosal
leeding
urprisingly,  there  are  no  therapeutic  guidelines  on  stress
lcer  prophylaxis  published  by  either  the  American  Gas-
roenterological  Association  (AGA)  or  the  American  College
f  Gastroenterology  (ACG).  In  1999  the  American  Society  of
ealth-System  Pharmacists  (ASHP)  issued  guides  for  the  use
f  these  drugs.27
These  evidence-based  guides  have  only  identiﬁed  2 main
isk  factors  in  ICU  patients  as  predictors  of  stress-induced
leeding  in  whom  prophylaxis  is  strongly  suggested  (strength
f  evidence  A):
.  Respiratory  Failure  (mechanical  ventilation  for  at  least
48  h)
0
h
b
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.  Coagulopathy  (ICU-hospitalized  patients  with  platelet
count  <  50,000;  INR  >  1.5;  abnormal  PTT).
Other  risk  factors  with  lower  degree  of  evidence  are:
.  Head  injury  <  10  Glasgow  scale  (B).
.  Thermal  injury  over  35%  BSA28 (B).
.  Partial  hepatectomy  (C).
.  Gastrointestinal  bleeding  or  ulcer  in  the  previous  year
(D).
.  Multiple  trauma  (Injury  Severity  Score  ≥  16)  (D).
.  Hepatic  failure  (D).
.  Spinal  cord  injuries27 (D).
.  Hepatic  or  renal  transplantation  (D)
.  More  than  2  of  the  following:  sepsis,  ICU  stay  >  1  week,
high  corticosteroid  dose  (>  250  mg  of  hydrocortisone  [D]),
occult  or  overt  bleeding  for  6  days  or  more  [D])
hich intensive care unit patients require
rophylactic therapy?
ecause  overt  gastrointestinal  bleeding  occurs  in  a  minor-
ty  of  ICU  patients  and  clinically  important  bleeding  in  only
-3%,  some  authors  have  argued  that  prophylaxis  is  now
verused.  Therefore,  the  question  is:  which  ICU  patients
hould  receive  prophylaxis?  Certainly,  patients  with  respi-
atory  failure  requiring  mechanical  ventilation  for  >  48  h  are
t  risk,  as  well  as  those  with  severe  coagulopathy.  Patients
resenting  with  closed  head  injury  and  a  low  Glasgow  score
r  severe  burns  should  also  receive  prophylactic  therapy.
atients  who  do  not  fall  into  any  of  these  groups  have  less
han  0.5%  risk  of  clinically  signiﬁcant  bleeding  and  probably
o  not  require  prophylactic  therapy.
rophylaxis
he  efﬁcacy  of  gastric  acid  inhibition  to  prevent  gastroin-
estinal  bleeding  is  conﬂicting.  Previously,  H2RAs  have  been
sed  successfully.  With  higher  acid  suppression  offered  by
PIs,  intensive  care  physicians  expected  better  results.  How-
ver,  the  evidence  is  not  solid.
Several  clinical  trials  have  evaluated  the  efﬁcacy  of
2RAs  for  the  prevention  of  stress-related  gastrointestinal
leeding.  A  meta-analysis  published  in  1998  showed  that
2RAs  were  signiﬁcantly  better  than  placebo  in  reducing
he  incidence  of  overt  and  clinically  important  bleeding.
his  study  also  reported  that  H2RAs  were  signiﬁcantly  better
han  sucralfate  in  reducing  clinically  important  bleeding  in
echanically  ventilated  patients.29
A  recent  meta-analysis  published  by  Marik  in  201030
ssessed  whether  prophylactic  administration  of  H2RAs  for
tress  ulcers  reduced  the  incidence  of  bleeding  compared
ith  placebo.  This  meta-analysis  analyzed  17  trials  with  a
otal  of  1,836  patients.  The  main  result  was  a  decrease
n  the  risk  of  bleeding  in  patients  with  acid  inhibitors
ompared  with  placebo  (odds  ratio  OR  =  0.47;  95%  CI,
.29-0.76;  p  <  0.002;  I2 =  44%).  Conversely,  several  studies
ave  shown  no  signiﬁcant  reduction  in  clinically  important
leeding  using  H2RAs,  compared  with  either  placebo  or
ucralfate.11,12,31,32
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The  use  of  PPIs  as  stress  ulcer  prophylaxis  has  increased
more  recently.  It  seems  that  PPIs  are  at  least  as  effective
as  H2RAs.  The  ﬁrst  meta-analysis  by  Pongrasobchai  in  2009,
found  that  prophylaxis  with  PPIs  was  associated  with  fewer
bleeding  events,  compared  with  H2RAs  (OR  =  0.42,  95%  CI,
0.20  to  0.91,  number  needed  to  treat  [NNT]  =  22).  There
were  no  differences  in  the  frequency  of  adverse  events,  such
as  nosocomial  pneumonia.33 A  second  meta-analysis  by  Lin
PC  et  al.  compared  PPIs  and  H2RAs  as  prophylactic  agents
in  critically  ill  patients.  This  meta-analysis  included  7  trials
and  936  patients.  There  was  no  difference  between  the  two
groups  for  this  main  endpoint.  They  also  failed  to  demon-
strate  any  difference  in  the  incidence  of  pneumonia  and
mortality  between  the  2  groups.34 Another  important  meta-
analysis  was  published  in  2012  by  Barkun  et  al.  and  included
a  total  of  13  studies  involving  1,587  patients.  They  found
that  prophylactic  PPI  administration  signiﬁcantly  decreased
the  incidence  of  bleeding  compared  with  H2RAs  (OR  =  0.30;
95%  IC  0.17-  0.54,  NNT  =  39,  without  statistical  heterogene-
ity  p  =  0.93,  I2 =  0.0%).  There  were  no  differences  for  the
development  of  nosocomial  pneumonia,  duration  of  ICU  stay,
and  mortality.  As  they  noted,  deﬁnitions  of  bleeding  var-
ied  among  the  studies,  treatment  included  different  drugs
(omeprazole,  pantoprazole,  rabeprazole,  lansoprazole,  ran-
itidine,  famotidine,  and  cimetidine),  dosage  and  route  of
administration,  analyses  included  abstracts,  the  study  qual-
ity  of  many  trials  was  poor,  and  some  trials  were  performed
on  Asian  patients  known  as  slow  metabolizers.35 The  most
recent  meta-analysis  evaluating  efﬁcacy  and  safety  of  PPIs
vs  H2RAs  was  published  in  2013  by  Alhazzani  and  Cook  from
McMaster  University  in  Canada.  They  included  fourteen  tri-
als  for  a  total  of  1,720  patients.  PPIs  were  more  effective
than  H2RAs  at  reducing  both  clinically  important  upper  gas-
trointestinal  bleeding  (RR  =  0.36;  95%  CI  0.19-0.68;  p  =  0.002;
a
b
a
Table  1  Common  medications  used  for  prophylaxis  of  stress-rela
Medication  Route  Normal  Renal  Fu
Histamine  2  Receptor  antagonists
Cimetidine  IV  50  mg/h,  contin
infusion
po, NG  tube  300  mg  every  6  h
Famotidine  IV  1.7  mg/h,  contin
infusion
po, NG  tube  20  mg  every  12  h
Sucrose-Aluminum  complex
Sucralfate  po,  NG  tube  1  g  every  6  h  
Proton Pump  Inhibitors.  No  adjustment  necessary.
Esomeprazole  po,  NG  tube,  IV  40  mg  per  day
Lansoprazole  po,  NG  Tube,  IV  15  or  30  mg  per  
Pantoprazole  po;  NG  Tube;  IV  40  mg  per  day
Omeprazole  po;  NG  tube,  JT,  DT  Two  40  mg  doses
6-8  h  ﬁrst  day,  t
20-40  mg  daily
po: orally; IV: intravenous; CCL: creatinine clearance; NG: nasogastric;53
2 =  0%;  NNT  with  prophylaxis  =  78)  and  overt  upper  gastroin-
estinal  bleeding  (RR  =  0.35;  95%  CI  0.21-0.59;  p  <  0.001;
2 =  15%;  NNT  with  prophylaxis  =  30).  There  were  no  differ-
nces  between  PPIs  and  H2RAs  in  the  risk  of  nosocomial
neumonia  (RR  =  1.06;  95%  CI  0.73-1.52;  p  =  0.76;  I2 =  0%),
CU  mortality  (RR  =  1.01;  95%  CI  0.83-1.24;  p  =  0.91;
2 =  0%),  or  ICU  length  of  stay  (mean  difference  --  0.54  days;
5%  CI  2.20  to  1.13;  p  =  0.53;  I2 =  39%).  No  trials  reported  on
.  difﬁcile  infection.  Nevertheless,  several  factors  suggest
aution  on  the  interpretation  of  these  results.  The  sub-
roup  analysis  based  on  trial  quality  suggested  that  there
ere  no  differences  in  the  treatment  effect  among  trials
f  higher  quality.  It  is  possible  that  suboptimal  trial  design,
uch  as  the  lack  of  blinding,  has  enhanced  the  observed  ben-
ﬁts  of  PPIs.36 Currently,  most  ICUs  are  using  PPIs  instead
f  H2RAs  as  stress  ulcer  prophylactic  agents.  In  a  limited
urvey  of  pattern  use,  the  standard  prophylactic  regimen
arely  included  intravenous  ranitidine.37 Most  U.S.  institu-
ions  appear  to  be  using  a variety  of  proton  pump  inhibitor
egimens,  including  intravenous  pantoprazole  40  mg/12  h,
0  mg/12  h,  or  an  80  mg  bolus  followed  by  8  mg/h  continuous
nfusion.  Other  regimens  being  used  include  lansoprazole
0  mg/12  h  and  esomeprazole  40  mg/12  h.  However,  there
re  few  published  data  to  support  the  use  of  intravenous
roton  pump  inhibitors  for  the  prevention  of  upper  gas-
rointestinal  bleeding  in  critically  ill  patients.  Furthermore,
H  data  for  intravenous  pantoprazole  in  ICU  patients  was
btained  in  patients  on  enteral  diet,  and  whether  this  phar-
acological  effect  could  be  similar  in  fasted  patients  is
nknown  and  requires  further  study.38 Table  1Finally,  early  enteral  feeding  had  been  postulated  as
 useful  tool  in  preventing  stress-related  gastrointestinal
leeding.  Enteral  nutrients  buffer  acid  and  may  act  as
 direct  source  of  mucosal  energy,  induce  secretion  of
ted  bleeding.
nction  Renal  Failure  Comments
uous If  CCL  <  30  ml/m
↓  30  mg/h
May  be  preceded  by  a
300  mg  loading  dose,
IV.
 300  mg  every  12  h  Daily  dose  should  not
exceed  2,400  mg
uous If  CCL  <  30  ml/min
0.85  mg/h
 If  CCL  <  30  ml/min
20  mg  once  daily
Use  with  caution  in
severe  renal  failure
day
 every
hen
 JT: jejunal tube; DT: duodenal tube.
5c
m
s
c
s
p
d
c
s
e
i
o
I
a
e
2
H
d
(
t
w
9
t
f
3
s
s
i
C
T
s
r
A
e
t
4
b
t
b
p
A
f
P
e
i
a
l
F
N
a
C
T
R
1
1
1
1
1
1
1
1
1
1
2
2
24  
ytoprotective  prostaglandins  and  mucus,  and  improve
ucosal  blood  ﬂow.39,40 In  addition,  enteral  feeding  has  been
hown  to  be  more  effective  in  raising  gastric  pH  >  3.5  when
ompared  with  either  PPIs  or  H2RAs41.  Therefore,  it  has  been
uggested  that  early  enteral  feeding  would  be  beneﬁcial  in
reventing  UGI  bleeding  secondary  to  stress-related  mucosal
isease.  Several  trials,  mainly  in  burn  patients,  have  con-
luded  that  early  enteral  nutrition  is  effective  in  preventing
tress-related  gastrointestinal  bleeding.42--44 However,  the
vidence  is  not  solid  enough  because  no  clinical  random-
zed  controlled  trial  has  prospectively  tested  the  inﬂuence
f  enteral  nutrition  on  the  risk  of  stress  ulcer  prophylaxis.
n  a  former  meta-analysis  by  Marik,  that  included  17  trials
nd  1,836  patients,  they  showed  that  patients  who  received
nteral  feeding  (3  studies  with  a  total  patient  population  of
62)  did  not  beneﬁt  from  the  stress  ulcer  prophylaxis  with
2RAs  (OR  =  1.26;  95%  CI  0.43-3.7).  On  the  whole,  H2RAs
id  not  increase  the  risk  of  hospital-acquired  pneumonia
OR  =  1.53;  95%  CI  0.89-2.61;  p  =  0.12;  I2 =  41%).  However,
his  complication  was  increased  in  the  subgroup  of  patients
ho  received  prophylaxis  and  were  fed  enterally  (OR  =  2.81;
5%CI  1.20-6.56;  p  =  0.02;  I2 =  0%).  Surprisingly,  hospital  mor-
ality  was  higher  in  those  studies  (n  =  2)  including  patients
ed  enterally  that  received  H2RAs  (OR  1.89;  95%  CI  1.04-
.44;  p  =  0.04,  I2 =  0%).  The  results  of  this  meta-analysis
uggest  that  in  patients  receiving  enteral  tube  feeding,
tress  ulcer  prophylaxis  may  not  be  required,  and  indeed,
t  could  increase  the  risk  of  complications.30
onclusions
he  incidence  of  clinically  important  bleeding  related  to
tress  ulcers  has  declined.  The  pathogenesis  of  stress-
elated  mucosal  disease  and  stress  ulcers  is  multifactorial.
dmission  to  the  hospital  or  the  ICU  alone  is  not  reason
nough  to  provide  prophylaxis.  Only  patients  with  respira-
ory  failure  requiring  mechanical  ventilation  for  more  than
8  h  and  those  with  coagulopathy,  head  injury,  and  severe
urns  are  at  signiﬁcant  risk  for  such  bleeding  and  are  likely
o  beneﬁt  from  prophylaxis.  However,  other  risk  factors  must
e  considered.  The  most  appropriate  prophylactic  agent  to
revent  stress-related  bleeding  remains  to  be  determined.
 few  years  ago,  H2RAs  were  the  most  widely  used  drug
or  prophylaxis.  However,  PPIs  are  increasing  in  acceptance.
PIs  are  at  least  as  effective  as  H2RAs,  but  they  are  more
xpensive,  and  there  is  still  limited  evidence.  We  must
ndividualize  every  patient  in  the  ICU,  evaluate  risk,  and
ssess  the  need  to  start  stress-  related  bleeding  prophy-
axis.
inancial disclosure
o  ﬁnancial  support  was  received  in  relation  to  this
rticle.onﬂict of interest
he  authors  declare  that  there  is  no  conﬂict  of  interest.
2J.M.  Avendan˜o-Reyes,  H.  Jaramillo-Ramírez
eferences
1. Anderberg B, Sjodahl R. Prophylaxis and management of stress
ulcers. Scand J Gastroenterol. 1985;20 Suppl 110:101--4.
2. Cho CH, Koo MWL, Garg GP, et al. Stress-induced gastric
ulceration: Its aetiology and clinical implications. Scand J Gas-
troenterol. 1992;27:257--62.
3. Jefferson MS. Stress-related mucosal disease in the intensive
care unit. An update on prophylaxis. Adv Crit. 2007;18:119--28.
4. Spirit MJ. Stress-related mucosal disease: Risk factor and pro-
phylactic therapy. Clin Ther. 2004;26:197--213.
5. Duerksen DR. Stress-related mucosal disease in critically ill
patients. Best Pract Res Clin Gastroenterol. 2003;17:327--44.
6. Mutlu GM, Mutlu EA, Factor P. GI complications in patients
receiving mechanical ventilation. Chest. 2001;119:1222--41.
7. Fennerty MB. Pathophysiology of the upper gastrointestinal
tract in the critically ill patient: Rationale for the therapeu-
tic beneﬁts of acid suppression. Crit Care Med. 2002;30 6
Suppl:S351--5.
8. Gudeman SK, Wheeler CB, Miller JD, et al. Gastric secretory and
mucosal injury response to severe head trauma. Neurosurgery.
1983;12:175--9.
9. Cook DJ, Fuller HD, Guyatt GH, et al., For the Canadian Critical
Care Trials Group. Risk factors for gastrointestinal bleeding in
critically ill patients. N Engl J Med. 1994;330:377--81.
0. Cook DJ, Heyland D, Grifﬁth L, et al., for the Canadian Criti-
cal Care Trial Group. Risk factors for clinically important upper
gastrointestinal bleeding in patients requiring mechanical ven-
tilation. Crit Care Med. 1999;27:2812--7.
1. Kantorova I, Svodova P, Scheer P, et al. Stress ulcer prophylaxis
in critically ill patients: A randomized controlled trial. Hepato-
Gastroenterology. 2004;51:757--61.
2. Faisy C, Guerot E, Diehl J, et al. Clinically signiﬁcant gas-
trointestinal bleeding in critically ill patients with and without
stress-ulcer prophylaxis. Int Care Med. 2003;29:1306--13.
3. Spirt MJ. Stress-related mucosal disease. Curr Treat Options
Gastroenterol. 2003;6:135--45.
4. Pimental M, Roberts DE, Bernstein CN, et al. Clinically signiﬁ-
cant gastrointestinal bleeding in critically ill patients in an era
of prophylaxis. Am J Gastroenterol. 2000;95:2801--6.
5. Schuster DP, Rowley H, Feinstein S, et al. Prospective evaluation
of the risk of upper gastrointestinal bleeding after admission to
a medical intensive care unit. Am J Med. 1984;76:623--30.
6. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact
of inappropriate use of stress ulcer prophylaxis in non-ICU hos-
pitalized patients. Am J Gastroenterol. 2006;101:2200--5.
7. Pham CQ, Regal RE, Bostwick TR, et al. Acid suppressive therapy
use on an inpatient internal medicine service. Ann Pharma-
cother. 2006;40:1261--6.
8. Avendan˜o-Reyes JM, Jaramillo HJ, Rodríguez-Lomelí M.
Inhibidores de la secreción ácida gástrica para proﬁlaxis de
úlceras por estrés, indicaciones apropiadas e inapropiadas y su
impacto económico en un hospital de segundo nivel en Mexicali
B.C. Med Int Mex. 2010;26:431--6.
9. Forgacs I, Loganayagam A. Overprescribing proton pump
inhibitors. Is expensive and not evidence based. BMJ.
2008;336:2--3.
0. Yang YX, Metz DC. Reviews in basic and clinical gastroenterology
and hepatology. Gastroenterology. 2010;139:1115--27.
1. Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive med-
ications and the risk of hospital-acquired pneumonia. JAMA.
2009;301:2120--8.
2. Insogna KL. The effect of proton pump-inhibiting drugs on min-
eral metabolism. Am J Gastroenterol. 2009;104 Suppl 2:S2--4.
3. Yang YX, Lewis JD, Epstein S, et al. Long-term proton
pump inhibitor therapy and risk of hip fracture. JAMA.
2006;296:2947--53.
it  
3
3
3
3
3
3
4
4
4
4Prophylaxis  for  stress  ulcer  bleeding  in  the  intensive  care  un
24. Dial S, Delaney JA, Barkun AN, et al. Use of gastric
acid--suppressive agents and the risk of community-
acquired Clostridium difﬁcile--associated disease. JAMA.
2005;294:2989--95.
25. Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppres-
sion by proton pump inhibitors as a risk factor for Clostridium
difﬁcile--associated diarrhea in hospitalized patients. Am J Gas-
troenterol. 2008;103:2308--13.
26. Dalton BR, Lye-Maccannell T, Henderson EA, et al. Proton pump
inhibitors increase signiﬁcantly the risk of Clostridium difﬁcile
infection in a low endemicity, non-outbreak hospital setting.
Aliment Pharmacol Ther. 2009;29:626--34.
27. American Society of Health-System Pharmacist. ASHP thera-
peutic guidelines on stress ulcer prophylaxis. Am J Health-Syst
Pharm. 1999;56:347--79.
28. Mc Alhany JC, Czaja AJ, Pruitt BA. Antiacid control of
complications from acute gastroduodenal disease after burns.
J Trauma. 1976;16:645--9.
29. Cook D, Guyatt G, Marshall J, et al. A comparison of sucral-
fate and ranitidine for the prevention of upper gastrointestinal
bleeding in patients requiring mechanical ventilation. N Engl J
Med. 1998;338:791--7.
30. Marik PE, Vasu T, Hirani A, et al. Stress ulcer prophylaxis in the
new millennium: A systematic review and meta-analysis. Crit
Care Med. 2010;38:2222--8.
31. Messori A, Trippoli S, Corrado A. Bleeding and pneumonia in
intensive care patients given ranitidine and sucralfate for pre-
vention of stress ulcer. Meta-analysis of randomized controlled
trials. BMJ. 2000;321:1103--6.
32. Ben-Benachem T, Fogel R, Patel RV, et al. Prophylaxis for stress
related gastric hemorrhage in the medical intensive care unit.
Ann Int Med. 1994;121:568--75.33. Pongprasobchai S, Kridkratoke S, Nopmaneejumruslers C. Pro-
ton pump inhibitors for the prevention of stress-related mucosal
disease in critically-ill patients: A meta-analysis. J Med Assoc
Thai. 2009;92:632--7.
455
4. Lin PC, Chang CH, Hsu PI, et al. The efﬁcacy and Safety of proton
pump inhibitors vs histamine-2 receptor antagonist for stress
ulcer bleeding prophylaxis among critical care patients: A meta-
analysis. Crit Care Med. 2010;38:1197--205.
5. Barkun A, Bardou M, Martel M. Proton pump inhibitors vs
histamine 2 receptor antagonists for stress-related mucoasal
bleeding prophylaxis in critically ill patients: A meta-analysis.
Am J Gastroenterol. 2012;107:507--20.
6. Alhazzani W,  Alenezi F, Jaeschke R, et al. Proton pump inhibitors
versus histamine 2 receptor antagonists for stress ulcer pro-
phylaxis in critically ill patients: A systematic review and
meta-analysis. Crit Care Med. 2013;41:693--705.
7. Maton PN. Review article: Prevention of stress related mucosal
bleeding with proton pump inhibitors. Aliment Pharmacol Ther.
2005;22:45--52.
8. Somberg L, Karlstadt R, Blatcher D, et al. Intermittent intra-
venous pantoprazole maintains control of gastric PH in intensive
care unit patients Abstract. Am J Gastroenterol. 2002;97
Suppl:S47.
9. Ephgrave KS, Kleiman-Wexler RL, Adair CG. Enteral nutrients
prevent stress ulceration and increase intragastric volume. Crit
Care Med. 1990;18:621--4.
0. Shorr LD, Sirinek KR, Page CP, et al. The role of glucose in pre-
venting stress gastric mucosal injury. J Surg Res. 1984;36:384--8.
1. Bonten MJ, Gaillard CA, Van Tiel FH, et al. Continuous enteral
feeding counteracts preventative measures for gastric coloniza-
tion in intensive care patients. Crit Care Med. 1994;22:939--44.
2. Raff T, Germann G, Hartmann B. The value of early enteral
nutrition in the prophylaxis of stress ulceration in the severely
burned patient. Burns. 1997;23:313--8.
3. Choctaw WT, Fujita C, Zawacki BE. Prevention of upper gastroin-
testinal bleeding in burn patients: A role of elemental diet. Arch
Surg. 1980;115:1073--6.
4. Pingleton SK, Hadzima SK. Enteral alimentation and gastroin-
testinal bleeding in mechanically ventilated patients. Crit Care
Med. 1983;11:13--6.
